0001140361-23-050235.txt : 20231030 0001140361-23-050235.hdr.sgml : 20231030 20231030165130 ACCESSION NUMBER: 0001140361-23-050235 CONFORMED SUBMISSION TYPE: 3 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20231018 FILED AS OF DATE: 20231030 DATE AS OF CHANGE: 20231030 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: KAWAS LEEN CENTRAL INDEX KEY: 0001822491 FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36183 FILM NUMBER: 231361008 MAIL ADDRESS: STREET 1: 4000 MASON ROAD, SUITE 300 STREET 2: BOX 352141 CITY: SEATTLE STATE: WA ZIP: 98195-2141 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Eiger BioPharmaceuticals, Inc. CENTRAL INDEX KEY: 0001305253 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 361004130 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 2155 PARK BOULEVARD CITY: PALO ALTO STATE: CA ZIP: 94306 BUSINESS PHONE: 650-279-9845 MAIL ADDRESS: STREET 1: 2155 PARK BOULEVARD CITY: PALO ALTO STATE: CA ZIP: 94306 FORMER COMPANY: FORMER CONFORMED NAME: Celladon Corp DATE OF NAME CHANGE: 20041005 3 1 form3.xml X0206 3 2023-10-18 0 0001305253 Eiger BioPharmaceuticals, Inc. EIGR 0001822491 KAWAS LEEN 1900 AVENUE OF THE STARS, #1000 LOS ANGELES CA 90067 true Common Stock 1667100 I See footnote Common Stock 2700000 I See footnote Ms. Kawas controls Propel Bio Management LLC, a Delaware limited liability company ("Propel Management"). Ms. Kawas also shares control of Propel Bio Partners LLC, a Delaware limited liability company ("Propel General Partner"). Ms. Kawas, Propel Management and Propel General Partner act as the investment advisor to, or general partner of, or otherwise provide discretionary advisory services to, one or more private investment funds, and such investment funds directly own 1,667,100 shares of Common Stock. Propel Management acts as the investment advisor to an investment company registered under the Investment Company Act of 1940, as amended, and such investment company directly owns 2,700,000 shares of Common Stock. Ms. Kawas expressly disclaims beneficial ownership of the shares of Common Stock reported herein except to the extent of any pecuniary interest. /s/ Leen Kawas 2023-10-30